west china hospital covid-19 vaccine west china hospital covid-19 vaccine west china hospital covid-19 vaccine is a covid-19 vaccine candidate developed by jiangsu province centers for disease control and prevention, west china hospital and sichuan university. west china hospital covid-19 vaccinevaccine descriptiontargetsars-cov-2vaccine typeprotein subunitclinical dataroutes ofadministrationintramuscularidentifiersdrugbankdb16443 part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal clinical trials in august 2020, westvac biopharma started phase i clinical trials with 168 participants in china. in november, westvac biopharma started phase ii clinical trials with 960 participants in china in february 2021, westvac biopharma started phase iib clinical trials with 4,000 participants in china. later, westvac biopharma is no longer on phase iib clinical trial. in june 2021, westvac biopharma started phase iii trials with 40,000 participants including indonesia, kenya, and the philippines. children and adolescents trials in august 2021 westvac biopharma started phase i/ii trials with 600 participants for children and adolescents aged 6-17.